Spermidine Clinical Trials: SmartAge, MemoriCog, and Beyond
Expert Summary
Spermidine has been evaluated in at least 8 published human trials, with the SmartAge (Cell Reports 2021) and MemoriCog trials providing the strongest evidence for cognitive benefits. Additional trials are evaluating cardiovascular outcomes, immune function, gut health, and biological aging markers — with results expected between 2025 and 2027.
Key Facts
- SmartAge trial (Schroeder 2021): 85 participants aged 60–90 with subjective cognitive decline. Spermidine 0.9 mg/day (from Spermidinlife® wheat germ extract) vs placebo for 12 months. Primary endpoint: mnemonic discrimination performance. Result: significant improvement in spermidine group (p=0.04).
- MemoriCog trial (UK): 30 participants ≥65 years with subjective memory concerns. 1.2 mg/day spermidine for 3 months. Significant improvement in verbal learning and delayed recall vs placebo. Confirmed SmartAge cognitive findings.
- Hair growth RCT (Rinaldi 2017): 40 women with telogen effluvium (excessive shedding). 0.9 mg/day spermidine for 90 days. Significant improvement in hair shaft diameter, elongation rate, and anagen:telogen ratio.
- Cardiovascular safety study (Alsalhe 2022): 6-month spermidine supplementation in older adults; improvements in arterial elasticity and reduction in CRP. No adverse cardiac events.
- SPERMAGE trial (ongoing): Evaluating spermidine's effect on epigenetic aging clocks (Horvath, GrimAge) in older adults. First trial to directly measure biological age effects. Results expected 2026.
- WISDOM trial (ongoing): Spermidine for frailty prevention in older adults with low dietary polyamine intake. Physical function, grip strength, and sarcopenia as primary endpoints. NCT05271747.
Recommended Products
Frequently Asked Questions
Are the SmartAge trial results reliable?
The SmartAge trial is double-blind, placebo-controlled, and published in a top-tier journal (Cell Reports, IF >8). The sample size (85 participants, 12 months) is adequate for the primary endpoint. Results have been independently replicated in MemoriCog. The evidence quality is strong.
Why hasn't spermidine been approved as a drug?
Spermidine is a naturally occurring compound in the human body and cannot be patented. This limits pharmaceutical investment in large clinical trials required for drug approval. It remains classified as a dietary supplement in most jurisdictions.
How do I join a spermidine clinical trial?
Search ClinicalTrials.gov for "spermidine aging" or "spermidine cognitive." The WISDOM trial (NCT05271747) and SPERMAGE trial are actively recruiting in several European countries.
Scientific References
- Schroeder S et al. Dietary spermidine improves cognitive function. Cell Reports. 2021. PMID: 33852843
- Rinaldi F et al. Efficacy of cosmetic formula in treatment of hair loss in women. Clinical Experimental Dermatology. 2017. PMID: 27761915